The Market for Molecular Point of Care (mPOC), 2023

Table of Contents

Chapter 1: Executive Summary

• Figure 1-1: Molecular Point of Care Market, 2022-2026 ($M)
• Figure 1-2: Near Patient Molecular Systems Market: 2022-2027 ($M)

Where is Molecular Point of Care in 2023?

• Table 1-1: Molecular Point of Care Market, 2022-2027 ($M)

Molecular Point of Care Market Analysis

• Table 1-2: Molecular Point of Care Market, 2022-2027 (%)
• Figure 1-3: mPOC Market by Disease Indication, 2022 (%; Respiratory, Other)

Market Observations

“Near-Patient” Molecular Systems Market

• Figure 1-4: mPOC and Near-Patient Market, 2022-2027
• Table 1-3: Near Patient Molecular Systems Market, 2022-2027 ($M and %)

Current Trends

Molecular Point-of-Care Diagnostics Defined

Usage of Molecular Point of Care

Leading mPOC Platforms

• Table 1-4: Molecular POC Diagnostic Platforms and Technologies

Trends

Scope and Methodology

 

Chapter 2: Molecular Point-of-Care Market Development and Trends

COVID-19 and Molecular POC

• Table 2-1: Molecular POC COVID-19 Emergency Authorizations

CDC Initial Response, Long Term Situation

COVID-19’s Unique Challenge

BARDA Directs Funding to mPOC

Recent Regulatory Developments

Consortia, Funding, Prizes

Deals

• Table 2-2: Deals in Molecular Point of Care, April 2019-January 2023

Advantages and Disadvantages of Molecular Point of Care

• Table 2-3: Disadvantages of Molecular Point of Care, by Setting (Physician Office Laboratory (POL) / Other Outpatient Settings, Developing and Low-Resource Areas, and Hospital POC)

Justification: The Sensitivity/Specificity Argument

New Systems and Menu Expansion

Mesa Biotech Strep A Approval

Combination Tests Enter Market: SARS-CoV-2, Flu A, Flu B, and RSV

STI Continues to Be a Growth Area

Deals, Investment in mPOC Systems

Thermo Acquires Mesa Biotech

EU Researchers Awarded €3M to Develop POC Molecular Tests

Scope Fluidics AST System Sees Investment

China as a POC Market

Common Tests and Analytes in POC Diagnostics

Component Technologies of Molecular Point-of-Care Diagnostics

Microfluidics

qPCR

Microarrays

Isothermal Amplification

Test Automation

Primers and Probes

Detection

Next-Generation Sequencing

Molecular Diagnostics

Real-Time PCR (qPCR)

Isothermal Amplification Methods

Line Probe Assays

Next-Generation Sequencing

Applications and Potential Applications for Molecular Point-of-Care

Major Testing Applications for Molecular POC Diagnostics

Influenza

Reclassification of RIDTs

Hospital-Acquired Infections (HAIs)

Strep A

Respiratory Syncytial Virus (RSV)

Emerging Applications

Zika

Other Respiratory Infections

Group B Streptococcus

Human Papillomavirus

Herpes Simplex Virus

Vaginitis

Tuberculosis

Malaria

Other Tropical and Neglected Diseases

Cancer

European Device Regulations Nearing

 

Chapter 3: Market Analysis

Molecular Point of Care Market Analysis

• Table 3-1: Molecular Point of Care Market, 2022-2027 ($M, %)
• Figure 3-1: Molecular Point of Care Market, 2022-2026 ($M)
• Table 3-2: Molecular Point of Care Market Share, by Vendor (Abbott, bioMérieux, Cepheid, Cue Health, Roche, Other), 2022 ($M, %)
• Figure 3-2: Molecular Point of Care Market Share, by Vendor (Abbott, bioMérieux, Cepheid, Cue Health, Roche, Other), 2022 (%)
• Table 3-3: Geographic Breakout of the Molecular Point of Care Market, 2022 (N. America, Europe, APAC, RoW)
• Table 3-4: Segment Breakout of Molecular Point of Care Market, 2022 (COVID-Respiratory vs. Other)
• Figure 3-3: Breakout of Molecular Point of Care Market (Respiratory, Other), 2022 (%)

“Near Patient Molecular” Market

• Table 3-5: Near Patient Molecular Systems Market, 2022-2027

Market Share Near Patient

• Figure 3-4: Market Share, Near Patient Molecular Testing, (Abbott, bioMérieux, Cepheid, Cue Health, Roche, Other), 2022

 

Chapter 4: Company Profiles

Abbott Laboratories

Aidian Oy

Akonni Biosystems

binx health, inc.

Biocartis NV

bioMérieux SA

• Table 4-1: bioMérieux FilmArray Est. Systems per Quarter, Q4 ’18-Q3 ’22
• Figure 4-1: FilmArray Systems Installed by Quarter, Q4 2018-Q3 2022

Cepheid (Danaher)

Molecular Healthcare-Acquired Infection (HAI) Testing

Molecular Sexual Health and Women’s Health Testing

Molecular Critical Infectious Disease Testing

Molecular Oncology/Genetics Testing

Credo Bioscience

Cue Health

Curetis NV (OpGen)

DiaSorin S.p.A

GenMark Diagnostics (Roche)

Greiner Bio-One GmbH

Lucira Health

Meridian Bioscience, Inc.

Mesa Biotech, Inc. (Thermo)

QIAGEN NV

QuantuMDx Group

QuidelOrtho Corporation

Roche

Sekisui Diagnostics LLC

T2 Biosystems